TiGenix – American Depositary Shares (NASDAQ:TIG) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday. The brokerage presently has a $26.00 price objective on the stock. Zacks Investment Research‘s price target suggests a potential upside of 9.80% from the company’s previous close.
According to Zacks, “TiGenix NV is a biopharmaceutical company. It focused on developing and commercializing novel therapeutics for allogeneic or donor-derived, expanded stem cells. The company’s product platform consists of Cx601 and Cx611 which are in clinical trial stage. It operates primarily in Madrid, Spain. TiGenix NV is based in Leuven, Belgium. “
Other equities analysts also recently issued reports about the company. Canaccord Genuity reiterated a “buy” rating and set a $30.00 target price (up from $22.00) on shares of TiGenix – American Depositary Shares in a research report on Wednesday, September 20th. BidaskClub upgraded TiGenix – American Depositary Shares from a “strong sell” rating to a “sell” rating in a research report on Wednesday, December 27th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $31.67.
An institutional investor recently bought a new position in TiGenix – American Depositary Shares stock. Nexthera Capital LP purchased a new stake in shares of TiGenix – American Depositary Shares (NASDAQ:TIG) during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 92,203 shares of the company’s stock, valued at approximately $1,438,000. TiGenix – American Depositary Shares accounts for about 0.7% of Nexthera Capital LP’s portfolio, making the stock its 23rd biggest position. Nexthera Capital LP owned approximately 0.71% of TiGenix – American Depositary Shares as of its most recent SEC filing. 5.31% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “TiGenix – American Depositary Shares (TIG) Raised to “Buy” at Zacks Investment Research” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/01/05/tigenix-american-depositary-shares-tig-raised-to-buy-at-zacks-investment-research.html.
TiGenix – American Depositary Shares Company Profile
TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TiGenix - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TiGenix - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.